Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M84,755Revenue (TTM) $M24,062Net Margin (%)9.1Altman Z-Score1.7
Enterprise Value $M97,540EPS (TTM) $0.9Operating Margin %14.8Piotroski F-Score7
P/E(ttm)43.2Beneish M-Score-2.5Pre-tax Margin (%)9.9Higher ROA y-yY
Price/Book6.710-y EBITDA Growth Rate %-0.2Quick Ratio0.8Cash flow > EarningsY
Price/Sales3.95-y EBITDA Growth Rate %-17.6Current Ratio0.9Lower Leverage y-yN
Price/Free Cash Flow74.4y-y EBITDA Growth Rate %13.2ROA % (ttm)3.7Higher Current Ratio y-yY
Dividend Yield %4.2PEG--ROE % (ttm)13.5Less Shares Outstanding y-yY
Payout Ratio %160Shares Outstanding M2,530ROIC % (ttm)12.8Gross Margin Increase y-yY

Gurus Latest Trades with AZN

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
AZNDodge & Cox 2016-06-30 Add0.19%$27.26 - $30.25
($29.03)
$ 33.5015%Add 24.89%32,532,723
AZNNWQ Managers 2016-06-30 Add0.03%$27.26 - $30.25
($29.03)
$ 33.5015%Add 13.06%572,985
AZNDavid Dreman 2016-06-30 Buy 0.02%$27.26 - $30.25
($29.03)
$ 33.5015%New holding1,321
AZNKen Fisher 2016-06-30 Add0.01%$27.26 - $30.25
($29.03)
$ 33.5015%Add 45.23%338,979
AZNDodge & Cox 2016-03-31 Add0.39%$27.95 - $33.95
($30.11)
$ 33.5011%Add 121.19%26,049,650
AZNNWQ Managers 2016-03-31 Reduce$27.95 - $33.95
($30.11)
$ 33.5011%Reduce -1.83%506,785
AZNKen Fisher 2016-03-31 Add$27.95 - $33.95
($30.11)
$ 33.5011%Add 5.33%233,409
AZNDodge & Cox 2015-12-31 Buy 0.39%$30.47 - $34.77
($32.84)
$ 33.502%New holding11,777,132
AZNNWQ Managers 2015-12-31 Add0.01%$30.47 - $34.77
($32.84)
$ 33.502%Add 5.24%516,215
AZNKen Fisher 2015-12-31 Add0.01%$30.47 - $34.77
($32.8)
$ 33.502%Add 692.95%221,606
AZNNWQ Managers 2015-09-30 Add0.09%$30.28 - $34.54
($32.89)
$ 33.502%Add 60.04%490,535
AZNMario Gabelli 2015-09-30 Sold Out $30.28 - $34.54
($32.89)
$ 33.502%Sold Out0
AZNKen Fisher 2015-09-30 Buy $30.28 - $34.54
($32.89)
$ 33.502%New holding27,947
AZNDavid Dreman 2015-06-30 Sold Out -0.16%$31.86 - $36.68
($34.24)
$ 33.50-2%Sold Out0
AZNNWQ Managers 2015-06-30 Add0.12%$31.86 - $36.68
($34.24)
$ 33.50-2%Add 486.45%306,510
AZNMario Gabelli 2015-06-30 Reduce$31.86 - $36.68
($34.24)
$ 33.50-2%Reduce -28.81%8,400
AZNDavid Dreman 2015-03-31 Reduce-0.01%$32.22 - $36.35
($34.74)
$ 33.50-4%Reduce -4.43%54,978
AZNNWQ Managers 2015-03-31 Reduce-0.01%$32.22 - $36.35
($34.74)
$ 33.50-4%Reduce -21.34%104,530
AZNMario Gabelli 2015-03-31 Reduce$32.22 - $36.35
($34.74)
$ 33.50-4%Reduce -40.70%23,600
AZNDavid Dreman 2014-12-31 Reduce-0.51%$33.58 - $37.69
($35.81)
$ 33.50-6%Reduce -75.42%57,528
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

AZN is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


AZN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
ASTRAZENECA PLC10% Owner 2014-11-12Sell2,000,000$1797.06view

Quarterly/Annual Reports about AZN:

    News about AZN:

    Articles On GuruFocus.com
    Dividend and Value Opportunities in the Large-Cap Pharmaceutical Space Apr 05 2016 
    Francis Chou Raises Stake in Resolute Forest Products Mar 20 2016 
    Signature Select Canadian Fund Second Quarter 2015 Market Commentary Sep 22 2015 
    Francis Chou Doubles Stake in AstraZeneca Aug 11 2015 
    Last Month Insiders Bought Over $300 Million Of This Biotech Jun 26 2015 
    Guru Stocks at 52-Week Lows: XOM, WMT, CVX, AZN, COP Jun 21 2015 
    Amgen And AstraZeneca’s Deal On Psoriasis Drug Faces Termination May 27 2015 
    Johnson & Johnson A Good Investment Despite Current Lows May 14 2015 
    Vanguard Adds to Four of Its Largest Stakes May 04 2015 
    HealthCare Stocks That Can Make Investors Healthier Apr 08 2015 

    More From Other Websites
    MedImmune won't be impacted by AstraZeneca sale of antibiotic business to Pfizer Aug 25 2016
    Business Highlights Aug 24 2016
    Pfizer on buying spree with AstraZeneca antibiotics deal Aug 24 2016
    Pfizer on buying spree with AstraZeneca antibiotics deal Aug 24 2016
    AstraZeneca Sells Antibiotics Business; Mallinkcrodt Sheds Imaging Unit Aug 24 2016
    Pfizer's $1.5 Billion Antibiotics Buy: Strategic Long-Term Planning Or Pre-Split Prep? Aug 24 2016
    AstraZeneca to sell antibiotic pills business to Pfizer Aug 24 2016
    AstraZeneca to sell antibiotic pills business to Pfizer Aug 24 2016
    Performance of AstraZeneca’s RI&A Segment in 2Q16 Aug 24 2016
    [$$] AstraZeneca and Pfizer strike $1.6bn antibiotics deal Aug 24 2016
    Why AstraZeneca Continued to Lose Market Share in ING Segment Aug 24 2016
    AstraZeneca to sell molecule antibiotics business to Pfizer Aug 24 2016
    AstraZeneca to sell molecule antibiotics business to Pfizer Aug 24 2016
    AstraZeneca selling antibiotic unit to Pfizer for $725M Aug 24 2016
    How Crestor Weakened AstraZeneca’s CVMD Segment in 2Q16 Aug 24 2016
    Pfizer to Acquire Rights to AstraZeneca's Antibiotics Business Aug 24 2016
    Is Hikma Pharmaceuticals plc the best FTSE 100 healthcare stock to own after today’s update? Aug 24 2016
    What does AstraZeneca plc’s deal with Pfizer mean for shareholders? Aug 24 2016
    AstraZeneca sells part of antibiotics unit to Pfizer Aug 24 2016
    Pfizer to buy antibiotics business from AstraZeneca Aug 24 2016

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)